MORPHOSYS AG O.N. news, videos and press releases - Page 9
For more news please use our advanced search feature.
MORPHOSYS AG O.N. - More news...
MORPHOSYS AG O.N. - More news...
- MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL
- DGAP-News: MorphoSys Reports First Quarter 2020 Results
- MorphoSys Reports First Quarter 2020 Results
- DGAP-News: Invitation to MorphoSys' First Quarter 2020 Results Conference Call on May 7, 2020
- Invitation to MorphoSys' First Quarter 2020 Results Conference Call on May 7, 2020
- DGAP-News: MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland ChinaMorphoSys AG:
- MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland China
- DGAP-News: MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer
- MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer
- DGAP-News: MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures
- MorphoSys Provides Update on Impact of COVID-19 on Business Operations and Precautionary Measures
- DGAP-News: MorphoSys Presents Results for Fiscal Year 2019
- MorphoSys Presents Results for Fiscal Year 2019
- DGAP-News: Invitation to MorphoSys' Year-End Results 2019 Conference Call on March 19, 2020
- DGAP-News: MorphoSys Resolves a Capital Increase to Implement the Purchase of 3,629,764 American Depositary Shares by Incyte Corporation
- MorphoSys Resolves a Capital Increase to Implement the Purchase of 3,629,764 American Depositary Shares by Incyte Corporation
- DGAP-News: MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab
- MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab
- DGAP-News: FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL
- FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL
- DGAP-News: MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
- MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
- DGAP-News: MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab
- DGAP-Adhoc: MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab
- MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab
- MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab
- DGAP-News: MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
- DGAP-News: First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL
- DGAP-News: MorphoSys AG: Corporate Calendar 2020
- DGAP-News: Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure
